| EA |
Report |
Net bookings (FQ1'27) |
BEAT |
pred ~$1.35B vs. cons ~$1.30B |
LOW |
| EA |
Report |
Net revenue (FQ1'27) |
IN-LINE |
pred ~$1.62B vs. cons ~$1.60B |
LOW |
| EA |
Report |
Diluted EPS (FQ1'27) |
IN-LINE |
pred ~$0.82 vs. cons ~$0.80 |
LOW |
| EA |
Guide |
FY27 forward guidance (bookings/EPS) |
UNKNOWN |
guide suspended ~N/A vs. cons ~N/A (FY27) — no guide issued during pendency |
HIGH |
| EA |
Guide |
CFIUS approval / deal-close timing |
UNKNOWN |
outside date ~09-28-2026 vs. original ~06-30-2026 (FQ1'27) — CFIUS sole remaining gate |
MEDIUM |
| EA |
Guide |
Quarterly dividend continuation |
UNCHANGED |
guide ~$0.19/qtr vs. prior ~$0.19/qtr (FQ1'27) — carry component of arb |
HIGH |
| EA |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.1% |
— |
HIGH |
| EA |
Return |
5-day cumulative residual |
+0.4% (STABILIZE) |
Stock is a locked ~0.5% merger-arb pinned $1.09 below the $210 cash bid; the P&L carries near-zero information value with no call and no guidance. Day-1 residual is effectively nil regardless of a bookings beat because price is anchored to deal close, not fundamentals. Over 5 days the residual stays flat-to-slightly-positive as the spread grinds toward $210 on CFIUS/timing headlines — not earnings revisions. Only a CFIUS setback or walk-away (large air-pocket toward the ~$168 unaffected level) breaks this; absent that, STABILIZE. |
HIGH |